Crossmark

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Crossref DOI link: https://doi.org/10.1186/s12962-018-0169-9

Published Online: 2019-01-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bussabawalai, Thanaporn

Thiboonboon, Kittiphong

Teerawattananon, Yot
Funding

Funding for this research was provided by:

The National Health Security Office, Thailand
License Information

Text and Data Mining valid from 2019-01-08
More Information

Article History

Received: 31 October 2017

Accepted: 27 December 2018

First Online: 8 January 2019

Document is current

Any future updates will be listed below